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Radical cystectomy with pelvic lymphadenectomy represents the gold standard for treatment of muscle-invasive bladder cancer.
Extent of the lymph node dissection and lymph node involvement during radical cystectomy are the most powerful prognostic
factors associated with poor oncological outcome. However, the optimal boundaries of the lymph node dissection during a
radical cystectomy are controversial. The published literature based mostly on retrospective studies suggests that increasing the
number of nodes excised may have therapeutic and diagnostic beneﬁts without signiﬁcantly increasing the surgical morbidity.
These conclusionsare, however, inﬂuenced by selection and surgeon biases, inconsistencies in the quality of the surgery, and node
count variability. In this paper, we establish the current understanding about the utility of lymphadenectomy during a radical
cystectomy for muscle-invasive bladder cancer.
1.Introduction
Bladder cancer (BC) is the seventh most prevalent cancer
worldwideandresultsinsigniﬁcantmorbidityandmortality.
In the United States, BC is the fourth most common cancer
in males and the ninth in females with an estimated 70,980
new cases and 14,330 deaths in 2009 [1]. Muscle-invasive
BC (MIBC) accounts for virtually all the mortality from
bladder cancer and represents more than a quarter (≈25–
40%) of all BC. MIBC spreads from the bladder in a
predictable stepwise manner to the lymph nodes and then
to visceral organs. Metastatic BC is incurable and invariably
fatal. For patients with MIBC, radical cystectomy (RC) with
pelvic lymphadenectomy (PLND) represents the mainstay of
therapy. The PLND during RC represents both a chance to
accurately stage the cancer as well as a chance to remove
all the cancer from the body. An extended PLND may have
prognostic and therapeutic beneﬁts. However, there is still
debate regarding the boundaries of adequate PLND during
RC. In this paper, we will deﬁne the state of art regarding the
extent of PLND and nodal prognostic factors and their eﬀect
on oncological outcomes of BC patients.
2.LymphaticDrainageof theBladder
The anatomy of lymphatic drainage of the urinary bladder
is critically important for deﬁnition of the boundaries for an
adequate PLND during RC. The bladder lymphatic drainage
has well-deﬁned origin from lymphatic plexus within its
wall, in the submucosa and extending into the muscles.
Lymphatic channels drain through anterior, lateral, and
posterior intercalated lymph nodes (LNs) located within the
perivesical fat. Eﬀerent lymphatics then drain to the external
iliac, obturator, internal iliac, and presacral LNs. Lymphatic
trunks leading from the pelvic LNs subsequently drain into
more proximal common iliac LNs and then to aortocaval
LNs [2, 3]. Skip lesions have been reported, but their rarity
suggests that the pelvic LNs are the primary landing site and
that metastasis occurs in an orderly progression [2, 4–8].
3.Surgical Boundariesofthe
Lymphadenectomy
Figure 1 shows the template of extended PLND during RC.
Extended PLND include LNs between the aortic bifurcation2 International Journal of Surgical Oncology
and common iliac vessels (proximally), the genitofemoral
nerve (laterally), the circumﬂex iliac vein and LN of Clo-
quet (distally), and the internal iliac vessels (posteriorly),
including the obturator fossa and the presacral LNs anterior
to the sacral promontory. An extended dissection may also
extend superiorly to the level of the inferior mesenteric
artery. Importantly, the PLND along the external iliac vessels
is completely circumferential while the proximal dissection
along the common iliac and great vessels includes anterior
andlateralnodaltissues[5,7,9].StandardPLNDdiﬀersinits
cranial boundary which is limited tothelevelofthecommon
iliac bifurcation. A limited PLND involves the lymph nodes
in the obturator fossa.
4.Incidenceof LymphNodeMetastasis
The incidence of positive LNs in RC specimens is between
18–30%asshownin Table 1.Predictably,theincidenceofLN
involvement correlates with T stage, grade, and presence of
lympho vascularinvasion (LVI) [5, 10, 11]. Table 2 shows the
correlation with stage in the largest RC series. The incidence
of LN metastasis is ≤5% for <T2, around 25% in T2, and
40–45% in T3/T4 BC.
5.Lymphadenectomy:Staging/Prognostic
Beneﬁts
Precise staging of LN status is an important clinico-
pathological prognostic parameter following RC. Nodal
involvement identiﬁes a high-risk group that has the worst
oncological outcomes and may beneﬁt from adjuvant sys-
temic therapies. Clearly, extending the ﬁeld of PLND will
increase the number of LNs removed and the chances
of identifying positive nodes [5, 23, 24, 33]. Vazina et
al. found 16% patients with T3/T4 disease to have LN
metastasis proximal to the boundaries of standard PLND
and 30% of patients with common iliac LN involvement
also had involvement of presacral LNs [10]. Steven and
Poulsen found 34.4% of positive LNs above the common
iliacbifurcation[24].AninadequatelyperformedPLNDmay
underestimate the true disease burden and underestimate
the need for potentially therapeutic adjuvant therapies. An
accurate PLND represents the best way to accurately stage
patients with MIBC.
6.Lymphadenectomy:TherapeuticBeneﬁts
Removal of involved lymph nodes theoretically can improve
survival as it decreases overall tumor burden and allows the
immune system and chemotherapeutics to target a smaller
number of cancer cells, potentially with greater eﬃcacy.
Indeed,recent retrospective and prospective nonrandomized
studies suggest a better oncological outcome from removing
more LNs via an extended PLND during RC. Proponents for
extended PLND note frequent involvement of nodes outside
the standard PLND templates [10, 24, 34]. Some studies
found more proximal LN metastases above the cranial
boundary of the standard PLND (≈20%) where common
iliac, presacral, and LNs above the aortic bifurcation were
involved in 15–23%, 6–8%, and 4–10%, respectively [3, 5].
Additionally, up to 50% of patients with limited LN involve-
ment can be rendered disease-free after extended PLND
[2, 5]. The beneﬁts of PLND in removing micrometastatic
disease appear to be signiﬁcant in BC. Extended PLND
requires an additional time but does not add signiﬁcantly to
the morbidity of the procedure [2, 35–37]. However, there
are other studies that did not ﬁnd an advantage for extended
PLND [6, 7, 11]. The diﬀerence between these studies may
reﬂect the selection criteria for the patients. Further, while
the removal of grossly negative but microscopically involved
LN may have a therapeutic beneﬁt, the removal of bulky
involved LN is unlikely to improve survival. The level of
PLND remains controversial and can only be determined by
well-designed carefully controlled prospective randomized
studies.
7.TherapeuticBeneﬁtsinNodeNegative
BladderCancer
The extent of PLND may act as a surrogate marker for
overall surgical quality and survival beneﬁts from PLND in
node negative patients during RC were reported [13, 15, 31,
38, 39]. A thorough extended PLND might decrease pos-
itive surgical margins, and, hence improve the oncological
outcome. The 5-year RFS with organ-conﬁned tumors was
85% with an extended dissection compared to 64% with
similar pathologyundergoingamore limitedPLND[31].We
recommend an extended PLND, whenever possible; even in
clinically node negative patients.
8.Nodal Prognostic Factors
The prognosis in patients with lymph node-positive disease
can be stratiﬁed by the stage of the primary bladder tumor,
extent of PLND, the number of lymph nodes removed, the
number of LNs involved (tumor burden), LN density, and
the presence of nodal extracapsular extension. We would like
to highlight the most commonly studied nodal prognostic
factors.
8.1. Number of Lymph Nodes Removed. The median nodal
counts reported from RC series is considerably variable and
ranges from 9 to 30 (Table 3). This number has been used as
a surrogate marker for the adequacy of PLND. A standard
PLND yields an average of 8–14 nodes while extending
PLND up to the aortic bifurcation often yields 25–45 nodes
[2, 31, 34]. Diﬀerent studies suggested diﬀerent cut point
for the number of LNs that should be removed to achieve
adequatePLND(Table 4).SEERdatashowed thatPLNDand
the number of LNs removed are variable, and dissection of
at least 10 to 14 nodes during RC is the most important
prognostic factor [40]. The number of LNs removed not
only suggests the completeness of the PLND, but may have
prognostic signiﬁcance in both LN positive and negative
patients [3, 13]. Koppie et al. could not ﬁnd a minimum
number of LNs to be suﬃcient for optimal oncologicalInternational Journal of Surgical Oncology 3
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Figure 1: Template of extended lymph node dissection during radical cystectomy.
outcomes. Instead, the probability of survival continued to
increase as the number of LNs removed increases [22].
Unfortunately, with the striking interinstitution and
intrainstitution variability in node counts and variability
within patients, it is hard to deﬁne an exact minimum
number of LNs to be removed. The same extended PLND
may yield 20 or 80 LN depending on the patient, exposure
to chemotherapy, surgical technique, institution at which
performed, pathologist examining the LNs, and protocol
used to evaluate LNs number. Thus, a cutoﬀ of 30 would
renderthesame extended PLNDinadequate oradequate.We
believethattheextentofPLNDismoreimportantmarkerfor
bettersurgicalquality,and,ﬁnally, oncologicaloutcomeuntil
pathologic processing and aforementioned variables can be
addressed.
8.2. Lymph Node Yield. Many factors might explain the
variability in node yield. Clinical, anatomical, pathological,
surgical, and institutional factors may play a role [2, 4].
Old age and associated comorbidities may hinder extended
PLND [2, 52]. There might be some anatomic variability
in the number of nodes present in diﬀerent individuals
[4]. Tumor stage may be associated with nodal yield [2, 4,
39]. On the other hand, negative margin status has been
associated with higher nodal yield [4, 47]. Recent BCG or
neoadjuvantchemotherapymighthaveaneﬀect,probablyby
causing inﬂammation and ﬁbrosis thus helping more nodal
yield [4]. Sending LNs in separate packages was reported to
increase the nodal yield [15, 34]. The method of pathologic
evaluation including the use of fat-clearing solutions may
play a role as well [2, 4]. While there were contradictory
reports about the eﬀect of surgeon volume on LN yield
[4, 47], academic or teaching hospitals with a higher RC
volume tend to report higher LN counts [4, 47, 53].Recently,
Fang et al. implement a policy that at least 16 LNs has to be
examined pathologically. They showed that implementation
of this policy can improve the survival due to increased
awareness to perform a more thorough PLND [50].
8.3. Number of Positive Nodes (Tumor Burden). The number
of positive LNs (tumor burden) is an important prognostic
factor following RC [3, 7, 13, 15, 41]. Recurrence and
survival are inversely related to an increasing number of
positive LNs. Some studies reported the absolute number of
LNs involved as an independent prognostic factor. Others
deﬁned cutoﬀ numbers for worse prognosis [40]. Herr et
al. determined a cut-oﬀ of 4 positive LNs [39], Steven
and Poulsen detrmined 5 positive LNS [24], and Stein4 International Journal of Surgical Oncology
Table 1: Incidence of lymph node metastasis in radical cystectomy.
References Year No. of patients No. of LN metastasis (%) of LN metastasis
Vieweg et al. [12] 1999 682 193 28.1
Leissner et al. [13] 2000 447 136 30.4
Herr and Donat [14] 2001 763 193 25.3
Stein et al. [15] 2001 1,054 246 23.3
Gschwend et al. [16] 2002 686 193 28.1
Madersbacher et al. [17] 2003 507 121 23.9
Vazina et al. [10] 2004 176 43 24.4
Leissner et al. [5] 2004 290 81 27.9
Abdel-Latif et al. [11] 2004 418 110 26.3
Nishiyama et al. [18] 2004 1,113 162 14.6
Fleischmann et al. [19] 2005 507 124 24.5
Hautmann et al. [20] 2006 788 142 18.0
Shariat et al. [21] 2006 833 198 23.8
Koppie et al. [22] 2006 1,110 243 21.9
Stein et al. [23] 2007 1,621 383 23.6
Steven and Poulsen [24] 2007 336 64 19.0
Wright et al. [25] 2007 5,201 1260 24.3
Ghoneim et al. [26] 2008 2,720 555 20.4
Osawa et al. [27] 2009 435 83 19.1
Bruins et al. [28] 2009 1,600 369 23.1
Stephenson et al. [29] 2010 763 178 23.3
Seiler et al. [30] 2010 840 162 19.3
Table 2: Correlation of pathological T stage with LN metastases.
Study Poulsen
et al. [31]
Viewg
et al. [12]
Stein
et al. [15]
Madersbacher
et al. [17]
Leissner
et al. [5]
Vazina
et al. [10]
Abdel-Latif
et al. [11]
Hautmann
et al. [20]
Ghoneim
and
Abol-Enein
[32]
Year 1998 1999 2001 2003 2004 2004 2004 2006 2008
period 1990–1997 1980–
1990
1971–
1997 1985–2000 1999–2002 1992–2002 1997–1999 1986–2003 1971–2000
Total no. of
patients 191 686 1054 507 290 176 418 788 2720
%o fL Nm e t a s t a s i s
pT0, pTis,
and pT1 3 1 0 52 24412
pT2a 18 9 18 17 13 16 7 10 8
T 2 b 2 5 2 3 2 73 4 2 24 02 54 11 9
p T 3 5 1 4 3 4 54 1 4 45 04 84 43 9
p T 4 4 4 4 1 4 5 5 06 53 6
T o t a l 2 6 2 8 2 32 4 2 82 42 61 82 0
et al. showed signiﬁcantly worse survival in patients with >8
metastatic LNs [41]. Furthermore, the study from Mansoura
showed a signiﬁcance diﬀerence in prognosis when strati-
fying positive LNs (1 versus 2–5 versus 5) [11]. This was
also the case in a population-based study from the SEER
database (1 versus 2 versus 3 versus >3) [25]. Collectively, It
is obviousthat largertumor burdenin LNs isassociated with
poor oncological outcomes. Further, bulky positive LNs are
invariably associated with a poor prognosis [29].
9.The Conceptof “LymphNodeDensity”
The LN density couldbe a useful prognostic conceptbecause
it combines the extent of PLND as indicated by the total
number of LNs removed and the tumor burden as indicated
by the number of positive nodes. Herr and Stein were the
ﬁrst to introduce the concept of LN density (number of
positive nodes/number of removed nodes) with a cutoﬀ of
20% to stratify outcomes [41, 42]. Table 5 describes theInternational Journal of Surgical Oncology 5
Table 3: Median number of lymph nodes removed in cystectomy series.
References Year No. of patients Median number of LNs removed (range)
Stein et al. [41] 2003 244 30 (1–96)
Herr [42] 2003 162 13 (2–32)
Kassouf et al. [43] 2006 108 12 (1–58)
Kassouf et al. [44] 2008 248 12 (2–58)
Fleischmann et al. [45] 2005 101 22 (10–43)
Wright et al. [25] 2008 1260 9 (1–75)
Steven et al. [24] 2007 64 27 (11–49)
Abdel–Latif et al. [11] 2004 110 18 (mean)
Lerner et al. [46] 1993 132 31 (3–96)
Leissner et al. [13] 2000 302 15 (1–46)
Herr et al. [47] 2004 268 10 (0–54)
Koppie et al. [22] 2006 1042 9 (0–53)
Poulsen et al. [31] 1998 117 25 (9–67) extended
Dhar et al. [48] 2008 336 (Cleveland Clinic) 22 (10–43) extended
322 (University of Bern)
Table 4: Suggested number of LNs to be removed to achieve better oncological outcomes.
References Year No. of patients Median number of LNs removed (range) Cut-oﬀ number of LNs to be removed
Stein et al. [41] 2003 244 30 (1–96) 15
Konety et al. [49] 2003 361 N/A 10–14
Herr [42] 2003 162 13 (2–32) 13
Kassouf et al. [44] 2008 248 12 (2–58) 12
Fleischmann et al. [45] 2005 101 22 (10–43) 5
Wright et al. [25] 2008 1260 9 (1–75) 10
Leissner et al. [13] 2000 302 15 (1–46) 16
Herr et al. [47] 2004 268 10 (0–54) 10
Herr et al. [39] 2002 322 8 (0–44) for N0 8 for N0
11 (1–25) for N+ 11 for N+
Fang et al. [50] 2010 349 17 (0–53) 16
Dangle et al. [33] 2010 120 37 (11–87) 23–27
Shirotake et al. [51] 2010 169 10 for N0 9 for N0
13 for N+
cut-oﬀ values suggested for LN density in diﬀerent studies
and the oncological outcomes based on these cut-oﬀ values.
A pooled analysis of MD Anderson and Memorial Sloan-
Kettering Cancer Centers showed that LN density is superior
to TNM nodal status in predicting oncological outcomes
after RC [36]. Nevertheless, this index can be useful only if
there is a standard number of nodes that have to be removed
and a standard levelof PLND.Certainly,a LN density of 20%
basedon1positiveLNoutof5LNsremovedisdiﬀerentthan
20% based on 8 positive out of 40 LNs. Perhaps, this is the
reason why there has not been widespread clinical use of this
parameter since its introduction in 2003.
10.ExtracapsularExtensionof Lymph
Node Metastasis
Extracapsular extension (perforation of the capsule of LN
by tumor tissue with extranodal growth) has recently
been shown to double the risk of recurrence when com-
pared to intranodal conﬁned LN metastasis. Fleischman
et al. evaluated 101 patients who underwent RC and
extended PLND for LN+ disease and analyzed the inﬂu-
ence of extracapsular extension (found in 58% of the
patients) on patient prognoses. Patients with extracap-
sular extension had a signiﬁcantly decreased recurrence
free survival (RFS) (median, 12 versus 60 months, P<
.001) and overall survival (OS) (median, 16 versus 60
months, P<. 001) compared with those with intran-
odal metastases. Multivariate analyses conﬁrmed that extra-
capsular extension of LN metastases was the strongest
negative predictor for RFS [19]. However, others did
not ﬁnd a signiﬁcant association between extracapsu-
lar extension and survival after RC, leading to issue of
whether this pathological ﬁnding is really of importance
[55].6 International Journal of Surgical Oncology
Table 5: Cut-oﬀ lymph node densities and their eﬀect upon oncologicaloutcomes.
References Year No. of patients Median number of LNs removed (range) Cut-oﬀ PLND 5-Y survival rates
Below cut-oﬀ Above cut-oﬀ
Stein et al. [41] 2003 244 30 (1–96) 20 17 44
Herr [42] 2003 162 13 (2–32) 20 8∗ 64∗
Kassouf et al. [43] 2006 108 12 (1–58) 25 11 38
Kassouf et al. [44] 2008 248 12 (2–58) 20 15∗ 55∗
Fleischmann et al. [45] 2005 101 22 (10–43) 20 15 41
Steven and Poulsen [24] 2007 64 27 (11–49) 20 25 47
Abdel–Latif et al. [11] 2004 110 18 (mean) 20 16 39
Wiesner et al. [54] 2009 152 33 (15–77) 11 8∗ 34∗
Osawa et al. [27] 2009 435 12 (1–80) 25 12∗ 51∗
All studies reported RFS except ∗reported CSS.
11.The Conceptof“Sentinel LymphNode”
The sentinel node is deﬁned as the initial site of lymphatic
drainage from a primary tumor. Determination of sentinel
node for BC should be on individualized basis rather
than on anatomic location of primary tumor due to the
variability of lymphatic drainage [4]. Ghoneim and Abol-
Enein introduced the concept of sentinel region (intrapelvic
LNs) rather than sentinel node [6, 7]. Involvement of the
intrapelvic LNs may be the ﬁrst step in nodal metastasis
in most BCs and skip lesions might be very rare [26, 47,
52, 55–57]. However, higher number of patients and longer
followup is needed before widespread practice is accepted.
Recently, Studer group used multimodality technique to
locate the primary lymphatic landing sites of the bladder.
Their technique counted upon cystoscopic-guided injection
oftechnetium nanocolloid followed bypreoperativeradioac-
tiveLN detectionwith SPECT/CTfollowed by intraoperative
veriﬁcation with gamma probe. They found that limited
pelvic PLND removed only about 50% of all primary
lymphatic landing sites while extending the PLND up to
the ureteroiliac crossing removed 90% [8]. Analysis of their
study proves that the template or extent of PLND is more
important than merely the number of LNs removed [58].
The concept of sentinel node remains investigational in BC.
If sentinel nodes could be accurately identiﬁed on individual
basis, this could guide the decision about the extent of
PLND.Although,extendedPLNDcanbesafelyandroutinely
performed with minimal additional morbidity, we do not
currently see a need to compromise outcomes of patients
with BC with a suboptimal nodal dissection and reliance on
frozen section analyses.
12.ATailoredApproachto Lymphadenectomy
Tailoring PLND based on the clinical stage, so that patients
with advanced tumors or evidence of nodal involvement
would be treated with an extended PLND, whereas those
with organ-conﬁned disease and no evidence of nodal
involvement would undergo standard PLND, has been
advocated. However, the use of clinical stage of the primary
tumor for determining of the extent of PLND is problematic
[38]. Understaging could happen in approximately half of
patients with clinically organ-conﬁned disease [38, 59].
Intraoperative ﬁnding including inspection and palpation
of more proximal lymphatic regions may miss a substantial
percentage of positive LNs [38]. If the morbidity of PLND is
minimal, then there should be minimal downside to the use
of an extended PLND in all patients. Currently, there are no
reliable models to guide the decision regarding the extent of
PLND.
13.MorbidityofLymphadenectomy
Early complications of 28% and perioperative mortality
rates of 2.6–3% have been reported in large RC series [15,
26]. An extended PLND may prolong operative time by
about 60 minutes. However, it does not appear to increase
morbidity or mortality compared to the standard approach
[2, 35–37]. Comparing LN positive versus LN negative cases,
extended versus standard PLND conﬁrmed that there are
no signiﬁcant diﬀerences in morbidity or mortality [2, 35–
37, 41]. Extended PLND is a safe option in experienced
hands that may improve oncological outcomes by decreas-
ing positive surgical margins and resection of undetected
micrometastases [36, 38]. Despite that the administration
of neoadjuvant radiation or chemotherapy before RC may
not increase the morbidity and mortality. Patients who have
received these treatments should be judged carefully before
performing an extended PLND, as there might be a higher
risk of complications [9, 35, 36].
14.Laparoscopic-/Robotic-AssistedSurgery
Laparoscopic-/robotic-assisted RC and PLND were reported
as safe feasible procedures with acceptable nodal yield and
potentiallyequivalentoncologicaloutcomestoopenRCwith
no added morbidities [56, 60]. Complete removal of the LN-
bearing tissue up to aortic bifurcation or inferior mesenteric
artery is more challenging using minimally invasive modal-
ities. Recently, extended PLND has been demonstrated with
the robotic system, with comparable LN yields [57, 61, 62].
We believe that without long-term functional and onco-
logic outcome data, laparoscopic- and robotic-assisted RCInternational Journal of Surgical Oncology 7
should be considered investigative techniques, and patients
chosen for these modalities should be appropriately selected
and counseled.
15. FutureDirections
Many ofthe controversiesregarding theextentand theutility
of PLND in RC stem from the fact that data in support
or against their use have been obtained from retrospective
analyses ofdatabases and trials. Assuch none ofthese studies
were powered to answer the questions regarding the utility
of PLND in RC. A multicenter prospective randomized
clinical trial is in the ﬁnal stages of approval by SWOG (PI:
Seth Lerner, Baylor College of Medicine), and it randomizes
patients to standard versus extended lymphadenectomy
during RC for bladder cancer. The trial is powered to
detect diﬀerences in survival and when completed may truly
establish the role of PLND on the outcomes of patients with
bladder cancer.
16.Conclusions
The incidence of nodal disease in BC is around 25% and is
inﬂuenced by other pathological factors, most importantly
the pT stage. Extended PLND may provide prognostic and
therapeutic advantages in both LN-positive and negative
patients without signiﬁcantly increasing morbidity. How-
ever, the extent of PLND during RC needs better deﬁnition
through prospective randomized studies with long-term
followup. Laparoscopic-/robotic-assisted RC and PLND are
still new modalities that need longer evaluation before
recommending for more patients.
Abbreviations
BC: Bladder cancer
MIBC: Muscle-invasive bladder cancer
RC: Radical cystectomy
PLND: Pelvic lymph node dissection =
lymphadenectomy
LN: Lymph node
LVI: Lymphovascular invasion
RFS: Recurrence-free survival
CSS: Cancer-speciﬁc survival
OS: Overall survival
SPECT/CT: Single-photon emission computed
tomography.
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